Novo Nordisk Expands Manufacturing Facility in Clayton

World's largest insulin supplier meets increasing demand for insulin analog

products in United States

Jun 21, 2007, 01:00 ET from Novo Nordisk Inc.

    CLAYTON, N.C., June 21 /PRNewswire-FirstCall/ -- Tomorrow, Novo
 Nordisk, a world leader in diabetes care, will open its $100 million,
 200,000-square-foot expanded facility in Clayton, North Carolina to meet
 the country's increasing demand for FlexPen(R), the world's number one
 selling popular prefilled insulin pen.
     The event marks the second expansion in three years of the company's
 only insulin manufacturing facility in the United States, doubling the
 company's domestic insulin filling capabilities and initiating the first
 domestic production of FlexPen(R). As a result, more than 50 jobs have been
 created. To date, Novo Nordisk has expanded its workforce in Clayton to
     "Novo Nordisk is proud to both open the door to exciting job
 opportunities in Johnston County, with its wealth of intellectual talent
 and skilled labor, and to expand access to safe and effective insulin
 products made in the United States," said Lars Nobert, vice president of
 the facility. "With this new commitment of resources in the United States,
 Novo Nordisk is fulfilling its pledge to change diabetes by helping to
 improve the lives of the millions of Americans living with the disease."
     The company has a Triple Bottom Line commitment to social and
 environmental responsibility. To date, more than 3,000 adults have
 completed courses at the Johnston County Workforce Development Center, an
 award-winning learning center made possible through donations, including a
 land donation for the center from Novo Nordisk.
     "By cultivating and maintaining an educated work force and creating
 exciting jobs in pharmaceutical manufacturing, Novo Nordisk is providing
 access to some of the best paying and most rewarding opportunities in the
 area," said Mike DeSherbinin, Director of the Johnston County Economic
 Development Office.
     The company has a history of social responsibility in the community.
 Last year the company raised $20,000 for the Johnston County United Way and
 is a regular contributor to the Juvenile Diabetes Research Foundation. To
 recognize its Danish heritage and enrich local high school principals and
 teachers, the company also sponsors a Danish-American exchange for
     "Novo Nordisk is a valued partner in the community offering local area
 residents one of the best possible work environments in the area, exciting
 training and career advancement programs, and generous donations," said
 Clayton Town Manager, Steve Biggs. "The company has demonstrated both
 leadership in the community and an ability to successfully manage growth
 and changes in Clayton."
     Approximately 54 million Americans have pre-diabetes, a condition that
 puts them at increased risk for diabetes, a chronic disease affecting
 nearly 21 millions Americans. Many people with diabetes take insulin to
 control their blood sugar (glucose). Insulin pens can be used instead of
 vials and syringes for giving insulin injections. FlexPen is exclusively
 available for use with the Novo Nordisk insulin analog product portfolio.
     Novo Nordisk Pharmaceutical Industries in Clayton is located on 3612
 Powhatan Road. The opening ceremony will take place Friday from noon until
 one o'clock.
     About Novo Nordisk
     Novo Nordisk is a healthcare company with an 84-year history of
 innovation and achievement in diabetes care. The company has the broadest
 diabetes product portfolio in the industry, including the most advanced
 products within the area of insulin delivery systems. In addition to
 diabetes care, Novo Nordisk has a leading position within areas such as
 hemostasis management, growth hormone therapy, and hormone therapy for
 women. Novo Nordisk's business is driven by the Triple Bottom Line: a
 commitment to economic success, environmental soundness, and social
 responsibility to employees and customers. With headquarters in Denmark,
 Novo Nordisk employs more than 23,600 employees in 79 countries, and
 markets its products in 179 countries. Novo Nordisk's B shares are listed
 on the stock exchanges in Copenhagen and London. Its ADRs are listed on the
 New York Stock Exchange under the symbol 'NVO'. For global information,
 visit; for United States information, visit

SOURCE Novo Nordisk Inc.